Effect of transarterial radioembolization therapy on survival in intrahepatic cholangiocellular carcinoma

Purpose: The aim of this study was to present the survival analyses of patients with intrahepatic cholangiocellular carcinoma who are ineligible forsurgical treatment and treated with transarterial radioembolization. Materials and Methods: Twenty-eight patients with intrahepatic cholangiocellular carcinoma who were not eligible for surgical treatment were included in this study. All patients were treated by trans arterial radioembolization. The survival time of the patients who were followed up after diagnosis was recorded. Kaplan-Meier survival analysis was used to calculate survival. Results: The mean age was 60.46 years. While minimum age of patients was 36 years, maximum age of patients 84 years. The median follow-up was 14 months (min:3, max:33). The median survival time of the patients was 22 months (min:3 months, max:33 months). In addition, the survival time of patients who received chemotherapy and patients who did not receive chemotherapy, patients with solitary tumor, patients with multifocal tumor, patients with tumor unilobar and patients with bilobar were calculated and no significant difference was found between the groups. Conclusion: Although modem chemotherapy has increased this survival rate, it has not been able to increase the median survival beyond 12 months. When these data are taken into consideration, it is seen that transarterial radioembolization treatment prolongs survival.